Fundraise

Carlsberg spinout Traitomic raises €20M to sell non-GM traits beyond barley

What's the deal? TraitomicDealroom has a profile for this one. Try Dealroom →, a Danish biotech spun out of CarlsbergDealroom has a profile for this one. Try Dealroom →, has raised €20 million in a Series A led by Sofinnova Partners. The Export and Investment Fund of Denmark, Footprint Firm, Nordic Foodtech VCDealroom has a profile for this one. Try Dealroom →, PSVDealroom has a profile for this one. Try Dealroom → Hafnium, and SVG VenturesDealroom has a profile for this one. Try Dealroom → joined the round.

What does it do? Traitomic uses FIND-IT, a screening platform developed at Carlsberg to improve barley, to find useful natural variants across plants and microbes — without directly editing genes. It says it has delivered 116 traits to 47 customers across 32 organisms, from crop improvement to industrial enzymes.

Licensed, not owned: Carlsberg keeps FIND-IT's IP and brewing rights; Traitomic holds an exclusive licence for all other uses. The round is the company's first external investment since the spinout, in which Carlsberg cut its stake to between 33% and 50%.

Why now? Traitomic is moving from Carlsberg subsidiary to independent growth business. "It's like a little bit of a teenager. Now we need to move out," chief executive Gustav Hambraeus said.

Where it's heading: Traitomic plans to expand into the US and Australia and broaden from trait discovery to end-to-end development inside customers' own crops and strains. The 30-person team currently has about 100 traits in pre-commercial assessment with clients.

By the numbers: The round sits in the top 8% of all Series A deals for food companies in Denmark on record, a notably large raise for the sector and geography.

What could go wrong? The open question is how many delivered traits reach a field or fermenter. New EU rules passed in June 2026 will ease regulation of some gene-edited plants from July 2028, potentially eroding the advantage of Traitomic's non-GM approach over gene-editing rivals such as Tropic and Rainbow Crops.

The signal: The round lands as European agtech funds both conventional crop improvement and gene editing — see OlsAro's €5 million for climate-resilient wheat and Rainbow Crops' €9.7 million for editing technology. Reported customer traction and a broad range of uses make Traitomic more than a speculative platform bet, but commercial scale-up remains the test.

Read more: Tech Funding News

Image credit: TRAITOMIC

More top stories